Hhamclav 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg. Amoxycillin, a broad-spectrum penicillin antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by beta-lactamase-producing bacteria, thereby enhancing its efficacy against resistant strains. This synergistic combination is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and sinusitis caused by susceptible organisms. Hhamclav 625 Tablet is effective against both gram-positive and gram-negative bacteria, providing a broad antimicrobial spectrum. It is administered orally, with dosage tailored according to the severity and type of infection, as well as patient-specific factors such as age and renal function. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypersensitivity reactions, although rare, can occur and warrant immediate medical attention. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Proper adherence to prescribed dosage and duration is essential to prevent resistance development and ensure therapeutic success.